Selectivity of the anthracyclines for negatively charged model membranes: role of the amino group - PubMed (original) (raw)
Selectivity of the anthracyclines for negatively charged model membranes: role of the amino group
T G Burke et al. Cancer Chemother Pharmacol. 1988.
Abstract
The equilibrium-binding affinities of six adriamycin analogues and four daunomycin derivatives for negatively charged dimyristoyl phosphatidylcholine/dimyristoyl phosphatidic acid (DMPC/DMPA) small unilamellar vesicles are compared with values for electroneutral DMPC liposomes. Binding of the daunomycin series to negatively charged dimyristoyl phosphatidyl glycerol (DMPG) vesicles was also examined. Under physiological conditions of pH and ionic strength, substitution of the amino group of adriamycin or daunomycin resulted in a reduced affinity for negatively charged bilayers, even if the substituent enhanced the degree of ionization of the amine. Decreasing the ionic strength increases the binding affinity for acidic membranes but decreases the drug affinity for neutral membranes. We propose that the electrostatic bond of the phosphate-amino group that has been shown to exist between anthracyclines and phosphatidic acid is sterically destabilized by substitution of the amino group. The results are consistent with a mode of anthracycline binding to negatively charged membranes which is driven by hydrophobic and electrostatic considerations but is destabilized by steric bulk at the amino group. The data also provide insight into the design of new anthracyclines with high membrane affinities and reduced uptake; such directed interaction with plasma membranes may enhance antineoplastic potential while reducing cardiac toxicity.
Similar articles
- Abrogation of the selectivity of adriamycin for negatively-charged phospholipids by 14-valerate side chain substitution.
Burke TG, Israel M, Seshadri R, Doroshow JH. Burke TG, et al. Cancer Biochem Biophys. 1990 Apr;11(2):177-85. Cancer Biochem Biophys. 1990. PMID: 2383860 - Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles. Circular dichroism study.
Gallois L, Fiallo M, Garnier-Suillerot A. Gallois L, et al. Biochim Biophys Acta. 1998 Mar 6;1370(1):31-40. doi: 10.1016/s0005-2736(97)00241-1. Biochim Biophys Acta. 1998. PMID: 9518541 - The overall partitioning of anthracyclines into phosphatidyl-containing model membranes depends neither on the drug charge nor the presence of anionic phospholipids.
Gallois L, Fiallo M, Laigle A, Priebe W, Garnier-Suillerot A. Gallois L, et al. Eur J Biochem. 1996 Nov 1;241(3):879-87. doi: 10.1111/j.1432-1033.1996.00879.x. Eur J Biochem. 1996. PMID: 8944778 - Interaction study between maltose-modified PPI dendrimers and lipidic model membranes.
Wrobel D, Appelhans D, Signorelli M, Wiesner B, Fessas D, Scheler U, Voit B, Maly J. Wrobel D, et al. Biochim Biophys Acta. 2015 Jul;1848(7):1490-501. doi: 10.1016/j.bbamem.2015.03.033. Epub 2015 Apr 3. Biochim Biophys Acta. 2015. PMID: 25843678
Cited by
- Liposomes as carriers of cancer chemotherapy. Current status and future prospects.
Kim S. Kim S. Drugs. 1993 Oct;46(4):618-38. doi: 10.2165/00003495-199346040-00004. Drugs. 1993. PMID: 7506649 Review. - Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.
Schwendener RA, Fiebig HH, Berger MR, Berger DP. Schwendener RA, et al. Cancer Chemother Pharmacol. 1991;27(6):429-39. doi: 10.1007/BF00685156. Cancer Chemother Pharmacol. 1991. PMID: 2013113 - Cell biological mechanisms of multidrug resistance in tumors.
Simon SM, Schindler M. Simon SM, et al. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3497-504. doi: 10.1073/pnas.91.9.3497. Proc Natl Acad Sci U S A. 1994. PMID: 7909602 Free PMC article. - Dye binding assay reveals doxorubicin preference for DNA versus cardiolipin.
Fox CA, Ryan RO. Fox CA, et al. Anal Biochem. 2020 Apr 1;594:113617. doi: 10.1016/j.ab.2020.113617. Epub 2020 Feb 8. Anal Biochem. 2020. PMID: 32045568 Free PMC article. - Membrane glycoprotein changes associated with anthracycline resistance in HL-60 cells.
Gervasoni JE Jr, Taub RN, Rosado M, Krishna S, Stewart VJ, Knowles DM, Bhalla K, Ross DD, Baker MA, Lutzky J, et al. Gervasoni JE Jr, et al. Cancer Chemother Pharmacol. 1991;28(2):93-101. doi: 10.1007/BF00689695. Cancer Chemother Pharmacol. 1991. PMID: 1711935
References
- Biochem Pharmacol. 1984 Feb 15;33(4):605-8 - PubMed
- Methods Cell Biol. 1976;14:33-71 - PubMed
- J Med Chem. 1979 Aug;22(8):912-8 - PubMed
- Cancer Res. 1985 Aug;45(8):3529-36 - PubMed
- Biochemistry. 1976 Apr 6;15(7):1393-401 - PubMed